This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cleveland BioLabs, Inc.
Drug Names(s): Protectan CBLB502, SA-702 Vaccine Adjuvant
Description: Protectan CBLB502 is recombinant derivative of the bacterial protein, flagellin, which binds and activates the mammalian TLR5 cell surface receptor. CBLB502 mobilizes several tissue protective mechanisms, including inhibition of programmed cell death (apoptosis), reduction of oxidative damage and induction of regeneration-promoting cytokines.
Cleveland and Roswell Park
In January 2007, Cleveland BioLabs announced that it has entered into a strategic research partnership with Roswell Park Cancer Institute to develop the Company's cancer and radio-protectant drug candidates.
Roswell Park and various agencies of the state of New York will provide Cleveland BioLabs with up to $5 million of non-dilutive funding. Cleveland BioLabs will establish a major research/clinical facility at the Roswell Park campus. The Company will have an open-ended license to any basic research conducted within or in collaboration with its Roswell Park laboratory.
Additional information available to subscribers only: